Affiliation:
1. Department of Diagnostic Radiology, Tokyo Medical and Dental University, Tokyo
Abstract
Abstract
From a clinical perspective, prostate-specific membrane antigen (PSMA) is a valuable target for both diagnosis and radioligand therapy (RLT) of prostate cancer. The term ‘specific’ has been used to characterize a histologic hallmark of overexpression in the membrane of most prostate cancer. Many PSMA ligands have been developed since the previous decade and have been used in several clinical trials and clinical studies. However, procedure, specification, protocol, interpretation criteria, radiation dose, and cost-effectiveness of PSMA ligands have not been fully explained. Regardless of worldwide use of promising PSMA-ligand PET and RLT, it has not been approved in Japan. Expedited introduction of PSMA-ligand PET and RLT to Japan and implementation of clinical study are eager for many patients with prostate cancer.
Funder
Ministry of Economy, Trade and Industry
Publisher
Oxford University Press (OUP)
Subject
Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine
Reference37 articles.
1. Identification, purification, and subcellular localization of prostate-specific membrane antigen PSMA protein in the LNCaP prostatic carcinoma cell line;Grauer;Cancer Res,1998
2. Progress in the discovery and development of glutamate carboxypeptidase II inhibitors;Tsukamoto;Drug Discov Today,2007
3. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: A new imaging probe for prostate cancer;Mease;Clin Cancer Res,2008
4. 2-(3-1-Carboxy-5-[(6-[18F]fluoro-pyridine-3-carbonyl)-amino]-pentyl-ureido)-pentanedioic acid, [18F]DCFPyL, a PSMA based PET imaging agent for prostate cancer;Chen;Clin Cancer Res,2011
5. [(18)F]fluoroethyl triazole substituted PSMA inhibitor exhibiting rapid normal organ clearance;Chen;Bioconjug Chem,2016
Cited by
23 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献